Los Angeles Capital Management’s Bright Minds Biosciences DRUG Stock Holding History

Los Angeles Capital Management’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.51M	Buy	+35,747	New	+$2.81M	0.01%	542

Other funds holding DRUG

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Trexquant Investment Stamford, Connecticut $17B AUM 39.66% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Los Angeles Capital Management's DRUG Position: Q2 2026 in Review

Los Angeles Capital Management opened a new position in Bright Minds Biosciences (DRUG) in Q2 2026: 35,747 shares worth $2.51M. The stake represents 0.01% of the portfolio and ranks #542 among its holdings.

55 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

Los Angeles Capital Management held 35,747 shares of Bright Minds Biosciences worth $2.51M as of Q2 2026.
Bright Minds Biosciences was a new Los Angeles Capital Management position in Q2 2026.
Bright Minds Biosciences made up 0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #542 holding.
55 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.